Arbutus Biopharma Corporation (NASDAQ:ABUS) trading with a subtraction of -$0.09 to $4.07 on Thursday, a downside of -2.16 percent. An average of 2,490,951 shares of common stock have been traded in the last five days. There was a fall of -$0.03 in the past week, and it reached a new high 10 times over the past 12 months. The last 20 days have seen an average of 2,885,018 shares traded, while the 50-day average volume stands at 2,753,907.
ABUS stock has decreased by -2.12% in the last month. The company shares reached their 1-month lowest point of $3.73 on 10/07/21. With the stock rallying to its 52-week high on 02/09/21, shares of the company touched a low of $2.43 and a high of $5.87 in 52 weeks. It has reached a new high 8 times so far this year and achieved 17.18% or $0.52 in price. In spite of this, the price is down -30.66% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
247 days have passed since Arbutus Biopharma Corporation (ABUS) last reported insider trading activity. McElhaugh Michael J., who is Chief Business Officer, most recently acquired $20,000 shares at $5.00 per share on Feb 09. In this transaction, the insider spent $100,000. Chief Business Officer, McElhaugh Michael J., disposed of 40,000 shares at a price of $5.00 on Dec 14. The insider now owns more than $200,032 worth of shares.
Arbutus Biopharma Corporation (ABUS) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.78 for the sector. The stock’s beta is 2.66. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 51.11.
The quick ratio of Arbutus Biopharma Corporation for the three months ended June 29 was 9.40, and the current ratio was 9.40, indicating that the company is able to meet its debt obligations. On the profitability front, the trailing 12-month gross margin 5-year average of -1362.7%. Arbutus Biopharma Corporation’s EBITDA margin for the year ending June 29 is -799.70%. Its gross profit as reported stood at $64.25 million compared to revenue of $6.91 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Arbutus Biopharma Corporation’s return on assets was -61.30%, compared to -60.3% over the last five years. For the broader industry, ROE averaged -68.79 over the past year.
For the three-month period that ended June 29, Arbutus Biopharma Corporation had $47.43 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$22.65 million in the quarter, while revenues of -$19.59 million were grew 24.59%. The analyst consensus anticipated Arbutus Biopharma Corporation’s latest quarter earnings to come in at -$0.22 per share, but it turned out to be -$0.23, a -4.50% surprise. For the quarter, EBITDA amounted to -$18.21 million. Shareholders own equity worth $99.16 million.
From a technical analysis perspective, let’s take a brief look at Arbutus Biopharma Corporation (ABUS) price momentum. RSI 9-day as of the close on 13 October was 45.31%, suggesting the stock is Neutral, with historical volatility in this time frame at 53.87%.
As of today, ABUS’s price is $4.12 -0.73% or -$0.03 from its 5-day moving average. ABUS is currently trading -5.57% lower than its 20-day SMA and +50.74% higher than its 100-day SMA. However, the stock’s current price level is +47.46% above the SMA50 and +16.29% above the SMA200.
The stochastic %K and %D were 41.91% and 42.35%, respectively, and the average true range (ATR) was 0.26. With the 14-day stochastic at 33.66% and the average true range at 0.26, the RSI (14) stands at 50.05%. The stock has reached 0.04 on the 9-day MACD Oscillator while the 14-day reading was at -0.05.
Jefferies launched coverage on Arbutus Biopharma Corporation (NASDAQ: ABUS) in its analyst report released on February 25, 2021. The firm assigned the stock a a Hold rating.The consensus rating for Arbutus Biopharma Corporation (ABUS) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ABUS, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 3 others rate it as a “buy”.
What is ABUS’s price target for the next 12 months?
Analysts predict a range of price targets between $4.00 and $10.00, with a median target of $5.00. Taking a look at these predictions, the average price target given by analysts for Arbutus Biopharma Corporation (ABUS) stock is $6.00.